DOES SWITCHING BETWEEN 5-AMINOSALICYLATES AFFECT THIOPURINE METABOLISM AND CLINICAL OUTCOMES IN PATIENT WITH ULCERATIVE COLITIS?

被引：0
|
作者：
Morikubo, Hiromu
Ozaki, Ryo
Okabayashi, Shinji
Kiyohara, Hiroki
Matsubayashi, Mao
Sagami, Shintaro
Nakano, Masaru
Ikezaki, Osamu
Hisamatsu, Tadakazu
Hibi, Toshifumi
Kobayashi, Taku
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1838
引用
收藏
页码：S1144 / S1144
页数：1
相关论文
共 50 条
  • [1] pH-Dependent 5-Aminosalicylates Releasing Preparations Do Not Affect Thiopurine Metabolism
    Takahashi, Kenichiro
    Bamba, Shigeki
    Morita, Yasuhiro
    Nishida, Atsushi
    Kawahara, Masahiro
    Inatomi, Osamu
    Sugimoto, Mitsushige
    Sasaki, Masaya
    Andoh, Akira
    DIGESTION, 2019, 100 (04) : 238 - 246
  • [2] Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism
    de Boer, Nanne K. H.
    Wong, Dennis R.
    Jharap, Bindia
    de Graaf, Peer
    Hooymans, Piet M.
    Mulder, Chris J. J.
    Rijmen, Frank
    Engels, Leopold G. J. B.
    van Bodergraven, Adrian A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (12): : 2747 - 2753
  • [3] Cost Effectiveness of Ulcerative Colitis Surveillance in the Setting of 5-Aminosalicylates
    Rubenstein, Joel H.
    Waljee, Akbar K.
    Jeter, Joanne M.
    Velayos, Fernando S.
    Ladabaum, Uri
    Higgins, Peter D. R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (09): : 2222 - 2232
  • [4] The Role of Chemoprevention of Colorectal Cancer with 5-Aminosalicylates in Ulcerative Colitis
    Herfarth, Hans
    DIGESTIVE DISEASES, 2012, 30 : 55 - 59
  • [5] Medical Management of Ulcerative Colitis with a Specific Focus on 5-Aminosalicylates
    Freeman, Hugh James
    CLINICAL MEDICINE INSIGHTS-GASTROENTEROLOGY, 2012, 5 : 77 - 83
  • [6] 5-aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis
    Walker, AM
    Szneke, P
    Bianchi, LA
    Field, LG
    Sutherland, LR
    Dreyer, NA
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1997, 92 (05): : 816 - 820
  • [7] DISCONTINUATION OF 5-AMINOSALICYLATES AFTER STARTING BIOLOGIC THERAPY IN PATIENTS WITH ULCERATIVE COLITIS IS NOT ASSOCIATED WITH ADVERSE OUTCOMES
    Limketkai, Berkeley
    Ungaro, Ryan C.
    Jess, Tine
    Allin, Kristine
    Agrawal, Manasi
    Ullman, Thomas A.
    Colombel, Jean Frederic
    GASTROENTEROLOGY, 2018, 154 (06) : S846 - S846
  • [8] Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
    Ford, Alexander C.
    Achkar, Jean-Paul
    Khan, Khurram J.
    Kane, Sunanda V.
    Talley, Nicholas J.
    Marshall, John K.
    Moayyedi, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04): : 601 - 616
  • [9] Letter: switches of 5-aminosalicylates in ulcerative colitis, risk of relapse and ascertainment bias
    Curtis, H.
    Jones, S.
    Treasure, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (03) : 344 - 345
  • [10] Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomes
    Limketkai, B.
    Ungaro, R.
    Jess, T.
    Allin, K.
    Agrawal, M.
    Ullman, T.
    Colombel, J. -F.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S287 - S288
12345